P8A Stock Overview
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cordlife Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.13 |
| 52 Week High | S$0.57 |
| 52 Week Low | S$0.12 |
| Beta | 0.54 |
| 1 Month Change | -34.21% |
| 3 Month Change | -59.02% |
| 1 Year Change | -60.94% |
| 3 Year Change | -65.28% |
| 5 Year Change | -71.26% |
| Change since IPO | -81.62% |
Recent News & Updates
Recent updates
Risks Still Elevated At These Prices As Cordlife Group Limited (SGX:P8A) Shares Dive 31%
Mar 22
Estimating The Fair Value Of Cordlife Group Limited (SGX:P8A)
Sep 07Cordlife Group (SGX:P8A) Will Be Hoping To Turn Its Returns On Capital Around
Aug 02Cordlife Group (SGX:P8A) Might Be Having Difficulty Using Its Capital Effectively
Apr 03Cordlife Group (SGX:P8A) Is Looking To Continue Growing Its Returns On Capital
Oct 15Cordlife Group's (SGX:P8A) Problems Go Beyond Weak Profit
Aug 22Shareholder Returns
| P8A | SG Healthcare | SG Market | |
|---|---|---|---|
| 7D | -13.8% | 0.2% | 2.6% |
| 1Y | -60.9% | -23.3% | -3.8% |
Return vs Industry: P8A underperformed the SG Healthcare industry which returned -23.3% over the past year.
Return vs Market: P8A underperformed the SG Market which returned -4.1% over the past year.
Price Volatility
| P8A volatility | |
|---|---|
| P8A Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in SG Market | 15.5% |
| 10% least volatile stocks in SG Market | 2.2% |
Stable Share Price: P8A's share price has been volatile over the past 3 months.
Volatility Over Time: P8A's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of SG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Pang Fai Yiu | www.cordlife.com |
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It offers cord blood, cord lining, and cord tissue banking services, including processing and storage of stem cells; and various diagnostics services, such as newborn genetic screening, pediatric vision and ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endometrial receptivity test, non-invasive prenatal testing, and newborn metabolic screening.
Cordlife Group Limited Fundamentals Summary
| P8A fundamental statistics | |
|---|---|
| Market cap | S$32.04m |
| Earnings (TTM) | S$3.71m |
| Revenue (TTM) | S$55.92m |
8.6x
P/E Ratio0.6x
P/S RatioIs P8A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P8A income statement (TTM) | |
|---|---|
| Revenue | S$55.92m |
| Cost of Revenue | S$18.43m |
| Gross Profit | S$37.50m |
| Other Expenses | S$33.78m |
| Earnings | S$3.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.014 |
| Gross Margin | 67.05% |
| Net Profit Margin | 6.64% |
| Debt/Equity Ratio | 0% |
How did P8A perform over the long term?
See historical performance and comparison